Medical News

RSS

$EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout$

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

30 Apr 2010

Women with family history of breast cancer face increase risk of ovarian cancer

Ovarian cancer is the most deadly disease of the female reproductive system, with most cases diagnosed in later stages. Yet while ovarian cancer affects 1 in 70 women in the United States, many women have never discussed the risk with their doctor.

30 Apr 2010

IPS examines how Uganda's anti-counterfeit bill could impact access to generic drugs

Inter Press Service examines Uganda's "controversial Counterfeit Goods Bill," which some say will limit the public's access to "life-saving generic medicines."

30 Apr 2010

Seniors often don't choose best quality Medicare Advantage plans, study finds

The Associated Press: "Millions of seniors signed up for popular Medicare Advantage insurance plans don't get the best quality, an independent study found. How the private plans score on a quality rating system set up by the government is about to have a direct impact on insurers' finances — not to mention seniors' benefits and premiums.

30 Apr 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended March 31, 2010 - the third quarter of the Company's 2010 fiscal year (3QFY10).

30 Apr 2010

Impax initiates challenge of patent listed by Shionogi Pharma concerning Fenoglide

Impax Laboratories, Inc. today confirms that it has initiated a challenge of a patent listed by Shionogi Pharma, Inc. in connection with its Fenoglide® (fenofibrate) tablets, 40 and 120 mg.

30 Apr 2010

Tel Aviv scientist uncovers a new way of detecting multiple sclerosis

Multiple sclerosis (MS) is an equal opportunity destroyer. It attacks the central nervous system and eventually renders most patients disabled. Among its high-profile victims are celebrated cellist Jacqueline du Pre, whose career was ended by MS, and Joan Didion, one of America's greatest writers - but they are far from alone.

30 Apr 2010

Study shows organic snackers underestimate calorie counts

Could organic labels lead you to overeat? These labels certainly appear to make people think their organic snack has a lot fewer calories than it really does.

30 Apr 2010

West Pharmaceutical Services reports 13.3% increase in first-quarter consolidated sales

West Pharmaceutical Services, Inc. today announced its results for the first quarter of 2010.

30 Apr 2010

Gonorrhea may soon become untreatable according to WHO

According to the World Health organization (WHO), gonorrhea may soon become untreatable and urgent measures need to be taken to prevent and treat the sexually transmitted infection. This is the result of improper use of first line antibiotics which has led to widespread anti microbial resistance to drugs. The cheaper antibiotics no longer have as much effect as they should and the higher antibiotics will soon lose efficacy as well.

30 Apr 2010

UC Irvine scientists receive CIRM grants for stem cell research

Two UC Irvine scientists will receive grants totaling more than $2.6 million to study the underlying biology of stem cells aimed at treating spinal cord injury, cancer and other disorders.

30 Apr 2010

Health insurers adopt reform changes early; WellPoint reports rising profits

Following announcements by leading health insurers that their firms would end the practice of rescission, or stripping the sick from their roles, the broader insurance industry followed suit, according to a letter from America's Health Insurance Plans to congressional Democrats, Politico reports. "The decision to end rescission … was made during a Tuesday afternoon conference call of chief executives organized by their trade group, America's Health Insurance Plans, and represents the industry's latest attempt to build political good will after the bruising health care fight."

30 Apr 2010

CSI announces completion of enrollment in CALCIUM 360° clinical trial for PAD

Cardiovascular Systems, Inc. (CSI), has completed patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company's 360° Clinical Series. The CALCIUM 360° feasibility study is evaluating the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI's Diamondback 360® System, a minimally invasive catheter for treating PAD anywhere in the leg. Dr. Nicolas Shammas, an interventional cardiologist at Trinity Medical Center, Bettendorf, Iowa, is the study's principal investigator.

30 Apr 2010

SickKids receives $8.9M grant for autism research

A research team co-led by Dr. Stephen Scherer, Senior Scientist at The Hospital for Sick Children (SickKids) was awarded an $8.9 million grant today from the Global Leadership Round in Genomics & Life Sciences (GL(2)), which is part of the Ontario Research Fund (ORF) by the Ministry of Research and Innovation (MRI).

30 Apr 2010

IRIC launches new RNA engineering laboratory in Canada

The Institute for Research in Immunology and Cancer of the Universit- de Montr-al is proud to announce the launch of the very first ribonucleic acid engineering laboratory in Canada.

30 Apr 2010

WellTek reports 115% increase in gross profit for fiscal year 2009

WellTek Incorporated, a global health, fitness and wellness company, is pleased to announce that the Company reported $2.54 million in revenue for the 2009 fiscal year ended December 31, 2009, representing a 15% increase over $2.20 million in revenue posted for 2008. The increase is primarily attributable to international sales by the Company's subsidiary, MedX Limited.

30 Apr 2010